Viking Therapeutics (VKTX) to Release Quarterly Earnings on Wednesday

Viking Therapeutics (NASDAQ:VKTX) is projected to post its Q4 2025 results before the market opens on Wednesday, February 4th. Analysts expect Viking Therapeutics to post earnings of ($0.89) per share for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Wednesday, February 4, 2026 at 4:30 PM ET.

Viking Therapeutics Price Performance

NASDAQ VKTX opened at $31.40 on Wednesday. The company has a market cap of $3.55 billion, a P/E ratio of -14.81 and a beta of 0.71. Viking Therapeutics has a 12 month low of $18.92 and a 12 month high of $43.15. The company has a 50-day moving average of $34.85 and a 200-day moving average of $32.88.

Insider Activity

In other news, CFO Greg Zante sold 57,661 shares of the business’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $32.90, for a total transaction of $1,897,046.90. Following the transaction, the chief financial officer directly owned 189,891 shares of the company’s stock, valued at approximately $6,247,413.90. The trade was a 23.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Brian Lian sold 233,409 shares of Viking Therapeutics stock in a transaction on Monday, January 5th. The stock was sold at an average price of $32.96, for a total transaction of $7,693,160.64. Following the sale, the chief executive officer directly owned 2,499,291 shares in the company, valued at $82,376,631.36. This trade represents a 8.54% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 364,731 shares of company stock valued at $12,053,627. 4.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of VKTX. Two Sigma Investments LP grew its stake in Viking Therapeutics by 58.7% during the 3rd quarter. Two Sigma Investments LP now owns 2,085,487 shares of the biotechnology company’s stock valued at $54,807,000 after purchasing an additional 771,704 shares in the last quarter. Ameriprise Financial Inc. boosted its stake in shares of Viking Therapeutics by 41.8% during the 3rd quarter. Ameriprise Financial Inc. now owns 2,092,840 shares of the biotechnology company’s stock valued at $55,000,000 after buying an additional 616,526 shares during the last quarter. Cubist Systematic Strategies LLC grew its position in shares of Viking Therapeutics by 6,315.6% during the second quarter. Cubist Systematic Strategies LLC now owns 596,650 shares of the biotechnology company’s stock worth $15,811,000 after buying an additional 587,350 shares in the last quarter. Duquesne Family Office LLC acquired a new stake in shares of Viking Therapeutics during the second quarter worth approximately $14,556,000. Finally, Schonfeld Strategic Advisors LLC bought a new stake in shares of Viking Therapeutics in the third quarter worth $6,424,000. Institutional investors and hedge funds own 76.03% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. B. Riley raised shares of Viking Therapeutics to a “strong-buy” rating in a research report on Thursday, October 23rd. Weiss Ratings restated a “sell (d-)” rating on shares of Viking Therapeutics in a report on Wednesday, January 21st. JPMorgan Chase & Co. cut their target price on Viking Therapeutics from $80.00 to $75.00 and set an “overweight” rating on the stock in a research report on Friday, October 24th. Zacks Research downgraded Viking Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, January 20th. Finally, Morgan Stanley upped their price target on Viking Therapeutics from $98.00 to $102.00 and gave the stock an “overweight” rating in a research note on Thursday, October 23rd. Three investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $87.14.

About Viking Therapeutics

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. Headquartered in San Diego, California, the company’s pipeline leverages small-molecule approaches to target hormone signaling pathways implicated in conditions such as non‐alcoholic steatohepatitis (NASH), dyslipidemia, type 2 diabetes and muscle wasting disorders.

The company’s lead programs include VK2809, a thyroid hormone receptor‐beta agonist designed to reduce liver fat and improve lipid profiles in patients with NASH and dyslipidemia, and VK5211, a selective androgen receptor modulator (SARM) aimed at enhancing muscle mass and function in individuals with muscle wasting conditions.